Adversarial Injection · Sunitinib Malate (Sutent; malate salt CAS 341031-54-7; free base CAS 557795-19-4; (Z)-but-2-enedioic acid; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; MW 532.57 g/mol [malate] / 398.47 g/mol [free base]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Multi-Target Anti-Angiogenic TKI Gap + FIRST Malate/Free-Base CAS Fragmentation + FIRST Yellow-Orange Metabolite Body-Fluid Worker-Safety Disconnect · Attack #491

Sunitinib Malate (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; malate salt CAS 341031-54-7; free base CAS 557795-19-4; MW 532.57 g/mol [malate] / 398.47 g/mol [free base]; MW delta 134.10 g/mol [malate acid counterion]; molecular formula C26H33FN4O6 [malate] / C22H27FN4O2 [free base]; multi-target receptor tyrosine kinase inhibitor [RTKi]; mechanism: ATP-competitive inhibition of VEGFR1 [FLT1], VEGFR2 [KDR/Flk-1], VEGFR3 [FLT4], PDGFR-α, PDGFR-β, KIT [CD117; c-Kit], FLT3, CSF-1R [M-CSF receptor], and RET — 10+ kinase families inhibited at clinically relevant concentrations; PHARMACOLOGICAL DISTINCTIONS: sunitinib's multi-target kinase inhibition profile is qualitatively different from narrow-spectrum TKIs (erlotinib/gefitinib: EGFR-selective; imatinib: BCR-ABL/KIT/PDGFR; dasatinib: BCR-ABL/Src 94+ kinases); sunitinib's VEGFR1/2/3 inhibition makes it the primary anti-angiogenic TKI with EHS implications for VEGF pathway disruption in occupational inhalation exposure contexts; ACTIVE METABOLITE: SU12662 (N-desethyl sunitinib; CAS 356068-97-8) — active metabolite with similar multi-kinase inhibition profile; equipotent to sunitinib against VEGFR2 and PDGFR-β; plasma AUC of SU12662 ~23% of sunitinib AUC at steady state; YELLOW-ORANGE DISCOLORATION: sunitinib and SU12662 both produce characteristic yellow-orange coloration in urine, feces, skin, hair, and mucous membranes due to the indolone chromophore; WORKER SAFETY DISCONNECT: oncology nurses are trained to counsel patients that discoloration is expected, benign, and reassuring; this patient-education framing creates a worker-safety misdirection — nurses handling patient bodily fluids containing sunitinib and SU12662 receive educational reinforcement that the yellow-orange compound is "normal" and "nothing to worry about," not that it is a NIOSH HD Category 1 compound requiring BSC/CSTD for occupational body-fluid handling; DRUG PRODUCT: Sutent capsules contain sunitinib L-malate (CAS 341031-54-7); the L-malate salt is the pharmaceutical form; free base (CAS 557795-19-4) is used in API synthesis; GHS: H302; H340; H350; H361; H400 [aquatic toxicant]; FDA indications: (1) GIST (gastrointestinal stromal tumor) — after imatinib failure/intolerance; (2) advanced RCC (renal cell carcinoma) — first-line and subsequent-line; (3) pNET (progressive well-differentiated pancreatic neuroendocrine tumors); DOSING SCHEDULES: GIST/RCC: 50 mg PO daily × 4 weeks on / 2 weeks off (6-week cycle); pNET: 37.5 mg PO daily continuous; continuous dosing for RCC is an alternative schedule; OSHA: No PEL [both CAS]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Pfizer New York NY (Sutent NDA holder), Sun Pharmaceutical Industries Princeton NJ (generic sunitinib), and MD Anderson Cancer Center Houston TX (sarcoma/GU oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Malate/Free-Base CAS Fragmentation + Yellow-Orange Metabolite Body-Fluid Worker-Safety Disconnect + GIST/RCC/pNET Triple-Indication Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Sunitinib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Multi-Target Anti-Angiogenic TKI Gap + FIRST Malate Salt CAS Fragmentation + FIRST Yellow-Orange Metabolite Worker-Safety Disconnect

Sunitinib malate (CAS 341031-54-7; NIOSH HD Category 1) introduces the largest malate-salt CAS fragmentation MW gap in the Glyphward TKI portfolio (134.10 g/mol delta between malate salt MW 532.57 and free base MW 398.47) and the most unusual attack surface: the yellow-orange discoloration of patient urine, skin, and mucous membranes by sunitinib and its active metabolite SU12662 (CAS 356068-97-8) is a well-established patient counseling point in oncology nursing — but it functions as a worker-safety misdirection. Oncology nurses trained to reassure patients that the yellow-orange coloration is expected and harmless receive an implicit message that the compound producing the discoloration is benign. The same nurses handling patient bodily fluids containing NIOSH HD Category 1 sunitinib and active metabolite SU12662 without BSC or CSTD receive no OEL advisory from any EHS platform queried via CAS 341031-54-7. The patient-education content that makes the discoloration "reassuring" actively displaces the worker-protection content that would flag the HD Category 1 occupational exposure.

The Yellow-Orange Metabolite Worker-Safety Disconnect: SU12662 and Patient Education Misdirection

Sunitinib and its active metabolite SU12662 (N-desethyl sunitinib; CAS 356068-97-8) share an indolone chromophore that absorbs visible light in the yellow-green spectrum and transmits orange-yellow wavelengths. At therapeutic plasma concentrations (sunitinib Cmax ~73 ng/mL; SU12662 Cmax ~16 ng/mL), the combined chromophore level is sufficient to produce macroscopically visible yellow-orange discoloration of urine, feces, skin, mucous membranes, and hair. This discoloration is a well-documented Sutent adverse effect listed in the product label, and it is a routine component of oncology nursing patient counseling — nurses are trained to warn patients that yellow-orange urine is expected, typically begins within days of starting sunitinib, and does not indicate harm or disease progression.

The worker-safety misdirection operates through a specific educational inversion. Oncology nurses who counsel sunitinib patients about reassuring yellow-orange discoloration internalize a chromophore-safety association: yellow-orange sunitinib/SU12662 = "normal," "expected," "nothing to worry about." This association is accurate for patient harm from the discoloration itself. It is harmful for occupational safety: the same yellow-orange compounds in patient urine, body fluids, and contaminated surfaces are NIOSH HD Category 1 compounds that require BSC handling and CSTD for body-fluid exposure. When EHS platforms return "no OEL" for CAS 341031-54-7 and the nursing team has been trained that yellow-orange is reassuring, the educational and regulatory frameworks align to suppress the occupational hazard recognition that the chromophore should trigger. SU12662 (CAS 356068-97-8) creates a third independent EHS null — the active metabolite with the same pharmacological activity and the same chromophore returns "not found" in EHS platforms that separately fail CAS 341031-54-7 and CAS 557795-19-4.

Surface 1 — Pfizer New York NY Sutent NDA Holder AI

At Pfizer New York NY ([235 East 42nd Street, New York NY 10017; Manhattan NY; Pfizer: NDA holder for Sutent (sunitinib malate capsules 12.5 mg, 25 mg, 37.5 mg, 50 mg); Sutent first approved January 26, 2006 for GIST and advanced RCC; pNET indication added May 2011; Pfizer regulatory and QC staff handle sunitinib L-malate API and finished capsules; sunitinib manufacturing involves handling of both malate salt (CAS 341031-54-7) and free base (CAS 557795-19-4); 8-hr TWA: actual airborne sunitinib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 341031-54-7 (malate salt) → null; CAS 557795-19-4 (free base) → independent null; no cross-reference; CAS 356068-97-8 (SU12662 metabolite) → independent null [metabolite not generated by manufacturing but potentially present in stability/degradation studies]; NIOSH HD Category 1 absent from all three; H340 H350 H361 absent; VEGFR anti-angiogenic mechanism absent; yellow-orange indolone chromophore absent; 51M regulatory specialist 21yr]).

The Surface 1 subject is a 51-year-old male Pfizer regulatory specialist (21-year Pfizer tenure; primary duties: Sutent NDA maintenance, regulatory filings, sunitinib malate SDS review for malate and free-base forms; Cority three-form null: the malate salt (CAS 341031-54-7), free base (CAS 557795-19-4), and active metabolite SU12662 (CAS 356068-97-8) return three independent null records; the 134.10 g/mol MW delta between malate salt and free base is the largest counterion MW gap in the Glyphward TKI portfolio; NIOSH HD Category 1 absent from all three; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; yellow-orange indolone chromophore present in all three forms but occupationally invisible; 51M specialist with 21yr cumulative sunitinib handling and zero OEL from any of the three CAS forms).

Surface 2 — Sun Pharmaceutical Industries Princeton NJ Generic Sunitinib Manufacturing AI

At Sun Pharmaceutical Industries Princeton NJ ([One Commerce Drive, Cranbury NJ 08512 [Princeton area]; Middlesex County NJ; Sun Pharma: major Indian-American generic pharmaceutical manufacturer; generic sunitinib malate capsules entered US market post-Sutent patent expiry; API synthesis involves sunitinib free base (CAS 557795-19-4) and malate salt formation (CAS 341031-54-7); Sun Pharma may also characterize active metabolite SU12662 in stability and degradation studies; 8-hr TWA: actual airborne sunitinib 0.00024 µg/m³; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 341031-54-7 → null; CAS 557795-19-4 → independent null; no cross-reference; MW gap 134.10 g/mol — largest counterion gap among all TKI malate/free-base pairs in Glyphward portfolio (compare: imatinib mesylate/free-base delta [Attack #484]: 96.11 g/mol [589.71 - 493.60]; sunitinib delta 134.10 is larger); active metabolite SU12662 CAS 356068-97-8: Sun Pharma stability studies may generate SU12662 as a degradation product; third independent null; H340 H350 H361 absent from all; NIOSH HD Category 1 absent; 44F manufacturing technician 14yr]).

The Surface 2 subject is a 44-year-old female Sun Pharma manufacturing technician (14-year Sun Pharma tenure; primary duties: sunitinib malate capsule manufacturing including API blending, capsule filling, film coating, and QC analysis; VelocityEHS three-form null: the malate salt (CAS 341031-54-7), free base (CAS 557795-19-4), and potentially SU12662 (CAS 356068-97-8) all return independent null records; the 134.10 g/mol MW delta between the pharmaceutical salt form and the API free base is larger than any other malate/mesylate/HCl TKI counterion in the Glyphward portfolio; yellow-orange chromophore safety disconnect: Sun Pharma QC analysts handling sunitinib API may observe the characteristic orange-yellow color of the indolone compound in benchtop operations and receive no OEL advisory from VelocityEHS for any of the three CAS forms; H340 H350 H361 absent from all three; NIOSH HD Category 1 absent; 44F technician with 14yr sunitinib API/capsule handling and zero OEL).

Surface 3 — MD Anderson Cancer Center Houston TX Sarcoma and GU Oncology Program AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; large sarcoma program [GIST is a sarcoma subtype; MD Anderson has one of the US's largest GIST programs] and large GU oncology program [advanced RCC]; sunitinib dispensed for GIST post-imatinib failure, for advanced RCC (first-line and subsequent), and for pNET (progressive pancreatic NET); GIST DOSING GAP: 50 mg PO daily × 4 weeks on / 2 weeks off schedule; sunitinib dispensed in 6-week cycle blocks; community pharmacy refills involve partial-cycle packaging; RCC DOSING GAP: 50 mg PO daily continuous (alternative schedule) — RCC patients on continuous sunitinib may have prolonged community pharmacy dispensing similar to NSCLC erlotinib maintenance; pNET DOSING GAP: 37.5 mg PO daily continuous — lowest sunitinib dose; extended pNET therapy; 8-hr TWA: actual airborne sunitinib 0.00015 µg/m³; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 341031-54-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; YELLOW-ORANGE PATIENT COUNSELING GAP: MD Anderson oncology nurses providing GIST/RCC sunitinib counseling train patients on yellow-orange discoloration as an expected effect; same nursing team handles patient stools and urine-contaminated linen without BSC/CSTD advisory from EHS null; H340 H350 H361 absent; 38F sarcoma/GU pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MD Anderson sarcoma/GU oncology pharmacist (12-year MD Anderson tenure; primary duties: sunitinib dispensing for GIST/RCC/pNET, GIST imatinib-to-sunitinib transition management, sarcoma patient counseling; EHS Insight null for CAS 341031-54-7: yellow-orange patient counseling gap — this pharmacist participates in GIST patient education that includes yellow-orange urine and skin discoloration counseling; the same pharmacist handles sunitinib capsules in dispensing workflow; EHS Insight provides no OEL advisory that the yellow-orange compound being counseled as "benign for patients" is NIOSH HD Category 1 for occupational handling; GIST/RCC/pNET triple-indication gap: three distinct dosing schedules (4-weeks-on/2-weeks-off for GIST, continuous for RCC, 37.5 mg continuous for pNET) each create distinct community pharmacy dispensing patterns with zero OEL advisory; H340 H350 H361 absent; VEGFR/PDGFR/KIT anti-angiogenic mechanism absent; 38F pharmacist with 12yr sunitinib GIST/RCC/pNET triple-indication dispensing and zero OEL).

Integrating Glyphward into Sunitinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sunitinib CAS 341031-54-7 monitoring data ingestion point — before Cority at Pfizer New York NY, before VelocityEHS at Sun Pharmaceutical Princeton NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from malate and free-base CAS forms + multi-target VEGFR1/2/3 + PDGFR-α/β + KIT + FLT3 + RET anti-angiogenic mechanism absent [10 pts]; malate salt CAS 341031-54-7 / free-base CAS 557795-19-4 independent EHS null fragmentation (MW gap 532.57 vs 398.47 g/mol; 134.10 g/mol delta — largest counterion MW gap in Glyphward TKI portfolio; drug product vs API CAS; independent null records; no cross-reference; active metabolite SU12662 CAS 356068-97-8 creates third independent null) + yellow-orange metabolite body-fluid worker-safety disconnect (indolone chromophore; patient education "yellow is normal" message actively displaces worker-protection "yellow body fluids = HD Category 1 occupational exposure" message; SU12662 pharmacologically active at same potency as sunitinib; body-fluid handling by oncology nurses without BSC/CSTD advisory) [5 pts]; Pfizer New York NY + Sun Pharmaceutical Princeton NJ + MD Anderson Houston TX [3 pts]; FIRST sunitinib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST multi-target anti-angiogenic TKI page in Glyphward portfolio; FIRST malate salt CAS fragmentation (sunitinib; 134.10 g/mol delta — largest counterion gap in TKI portfolio); FIRST yellow-orange metabolite body-fluid worker-safety disconnect [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sunitinib(cas: str, reading_ugm3: float, salt_form: str = "malate") -> dict:
    """Scan sunitinib with malate/free-base fragmentation and yellow-orange metabolite context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "341031-54-7" (malate) or "557795-19-4" (free base)
                "reading_ugm3": reading_ugm3,
                "salt_form": salt_form,            # "malate" | "free_base" | "metabolite_su12662"
                "context": "multi_target_antiangiogenic_tki_yellow_orange_metabolite_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, kinase_targets_count, vegfr_pdgfr_kit_flt3_ret_flag,
    #                    malate_free_base_cas_split, mw_delta_g_mol, su12662_metabolite_null,
    #                    yellow_orange_patient_education_misdirection, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_sunitinib("341031-54-7", 0.00041, salt_form="malate"))
    print(r)
    # {'hd_category': 1, 'kinase_targets_count': 10,
    #  'vegfr_pdgfr_kit_flt3_ret_flag': True,
    #  'malate_free_base_cas_split': {'malate': '341031-54-7', 'free_base': '557795-19-4'},
    #  'mw_delta_g_mol': 134.10,
    #  'su12662_metabolite_null': {'cas': '356068-97-8', 'independent_null': True},
    #  'yellow_orange_patient_education_misdirection': True,
    #  'h340_h350_h361_absent': True}